Streetbeat News

Price Targets

SIGI

B of A Securities analyst Grace Carter maintains an Underperform rating on Selective Insurance Group (NASDAQ:SIGI) but raises the price target from $89 to $96.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 5:31 pm

VLO

Scotiabank analyst Paul Cheng maintains a Sector Outperform rating on Valero Energy but lowers the price target from $173 to $141.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 5:30 pm

RNR

B of A Securities has maintained a Buy rating on RenaissanceRe Holdings and raised the price target from $364 to $391, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 5:29 pm

PSX

Scotiabank analyst Paul Cheng maintains a Sector Outperform rating on Phillips 66 but lowers the price target from $145 to $136.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 5:28 pm

PRU

B of A Securities has maintained a Neutral rating on Prudential Financial (NYSE:PRU) while raising the price target from $109 to $118.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 5:27 pm

PBF

Scotiabank analyst Paul Cheng has maintained a Sector Perform rating on PBF Energy but has lowered the price target from $45 to $31.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 5:27 pm

MPC

Scotiabank analyst Paul Cheng maintains a Sector Outperform rating on Marathon Petroleum but lowers the price target from $191 to $170.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 5:26 pm

PGR

B of A Securities has maintained a Buy rating on Progressive (NYSE:PGR) and raised its price target from $309 to $319, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 5:26 pm

DINO

Scotiabank analyst Paul Cheng maintains a Sector Outperform rating on HF Sinclair (NYSE:DINO) but lowers the price target from $66 to $57.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 5:25 pm

AKBA

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating for Akebia Therapeutics (NASDAQ:AKBA) and maintained a price target of $7.5.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 5:24 pm